Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 9.71% on Wednesday following the release of its third-quarter 2025 financial results, which fell significantly short of analyst expectations. The biotechnology company, specializing in AI-powered drug discovery, reported disappointing figures that triggered a sell-off among investors.

For the third quarter, Absci reported revenue of $378,000, representing a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million.

Despite the challenging financial results, Absci reported some positive developments in its drug pipeline. The company announced interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026. However, these advancements were not enough to offset investor concerns about the company's declining revenue and expanding losses, leading to the significant stock price decline.